Clinical Trials Logo

Filter by:
NCT ID: NCT03570957 Completed - Clinical trials for Seasonal Allergic Rhinitis

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Start date: July 17, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of MT-2990 in patients with Japanese cedar pollen-induced seasonal allergic rhinitis (JC-SAR). Additional objective of the study is to investigate the efficacy and pharmacodynamics profile of MT-2990 in an environmental exposure chamber (EEC) on Day 8, 29, 57, and 85.

NCT ID: NCT03570892 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

BELINDA
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

NCT ID: NCT03570749 Active, not recruiting - Alopecia Areata Clinical Trials

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

BRAVE-AA1
Start date: September 24, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.

NCT ID: NCT03570047 Completed - Clinical trials for Non-valvular Atrial Fibrillation

Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation

CER3
Start date: May 8, 2018
Phase:
Study type: Observational

An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of thromboembolism and it had long been the only oral anticoagulant until the first non-vitamin K antagonist oral anticoagulants (NOACs). However, its safety and effectiveness remains unknown in real-world clinical practice in Japan

NCT ID: NCT03569436 Completed - Clinical trials for Cancer of Head and Neck

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Start date: February 14, 2018
Phase:
Study type: Observational

Non-interventional study in Japan of participants with HNC recurring or that has spread and who are treated with nivolumab

NCT ID: NCT03569293 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

Measure Up 1
Start date: August 13, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

NCT ID: NCT03568461 Active, not recruiting - Follicular Lymphoma Clinical Trials

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

ELARA
Start date: November 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

NCT ID: NCT03568435 Completed - Kidney Cancer Clinical Trials

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Start date: February 14, 2018
Phase:
Study type: Observational

A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer

NCT ID: NCT03568318 Enrolling by invitation - Atopic Dermatitis Clinical Trials

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

AD Up
Start date: August 9, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

NCT ID: NCT03568175 Completed - Clinical trials for Mucopolysaccharidosis II

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Start date: August 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II.